PharmaTher Partners with KetaMist Inventor to Accelerate FDA Approval of Needle-Free Ketamine Therapy

Strategic Motivation for the KetaMist Partnership

PharmaTher's collaboration on KetaMist aligns with its strategic shift toward personalized medicines in peptides and psychedelics. The patient-controlled delivery model of KetaMist supports individualized treatment adjustments rather than standardized dosing, reinforcing PharmaTher's commitment to personalized therapies. This move follows the company's December 2025 sale of its ketamine hydrochloride injection ANDA, marking a transition away from generic ketamine formulations.

The partnership allows PharmaTher to capitalize on its regulatory and pharmaceutical development expertise in ketamine. Retaining rights to non-generic ketamine opportunities post-ANDA sale, PharmaTher is positioned to explore innovative formulations and delivery technologies. KetaMist's needle-free, patient-controlled platform fits this strategic focus and offers competitive advantages in a market with established ketamine therapies. The timing coincides with growing regulatory momentum for ketamine-based mental health treatments, potentially facilitating expedited development discussions.

KetaMist's Clinical Experience and Real-World Data

KetaMist has been used in over 9,000 patient treatments, providing a robust real-world clinical foundation. This extensive treatment history offers data on dosing, administration, safety, and patient outcomes, enabling PharmaTher to potentially streamline FDA development without starting from early-stage trials. The platform is designed as a proprietary, needle-free, patient-controlled ketamine system tailored for treatment-resistant depression and other neuropsychiatric conditions, allowing personalized dosing by physicians.

PharmaTher plans to evaluate and organize existing real-world data to support regulatory submissions and prepare documentation for FDA engagement aimed at an expedited approval pathway.

Market Overview and Competitive Positioning in Treatment-Resistant Depression

Treatment-resistant depression affects millions in the U.S., representing a significant unmet medical need. Esketamine nasal spray (Spravato), the current FDA-approved ketamine-based therapy, generated approximately $1.7 billion in global sales in 2025. Analyst forecasts project Spravato's sales could reach $3 billion annually by 2027 and peak at $5 billion, underscoring the market's commercial potential.

PharmaTher believes KetaMist can compete effectively by offering a differentiated approach featuring patient-controlled, needle-free delivery, personalized dosing, and a simplified administration method that may enhance patient comfort and access. Unlike esketamine, KetaMist uses racemic ketamine and may achieve broader clinical adoption depending on regulatory outcomes and labeling, positioning it as a distinct alternative to current market leaders.

Expansion Strategy Across Multiple Indications

While initially targeting treatment-resistant depression, PharmaTher envisions KetaMist as a platform with broader therapeutic applications. Potential future indications include depression, anxiety disorders, PTSD, chronic pain, and other neuropsychiatric and neurological conditions, many of which currently involve off-label ketamine use.

The company's franchise strategy leverages ketamine's established pharmacology and clinical utility, with KetaMist's patient-controlled design enabling development across multiple indications. This multi-indication approach may diversify revenue streams and establish market presence across several large therapeutic areas, contingent on successful FDA engagement and approvals.

PharmaTher's Regulatory and Development Expertise in Ketamine

PharmaTher previously secured FDA approval for Ketamine Hydrochloride Injection USP under ANDA 217858, demonstrating its capability to meet regulatory, manufacturing, analytical, and quality standards. Despite selling this ANDA in December 2025, the company retains substantial regulatory and product development expertise from the program, including knowledge of regulatory pathways, analytical methods, manufacturing controls, and quality assurance specific to ketamine pharmaceuticals.

In the KetaMist collaboration, PharmaTher intends to apply this expertise to guide development and seek FDA feedback on efficient approval pathways. The company's prior success positions it to navigate regulatory discussions effectively and potentially streamline KetaMist's approval process.

FDA Regulatory Strategy and Development Milestones

PharmaTher and Dr. Cassidy plan to collaborate with the FDA to identify an efficient approval pathway for KetaMist. Given ketamine's existing FDA approval as a pharmaceutical ingredient, the company aims to leverage established safety profiles and regulatory knowledge. The extensive real-world treatment experience from over 9,000 patients may support a more efficient regulatory approach than conventional drug development.

Near-term plans include preparing an FDA meeting package to obtain guidance on accelerated approval pathways, engaging regulators, defining clinical and data requirements for a potential NDA, and evaluating how real-world data can support development. PharmaTher notes increasing regulatory openness to development strategies incorporating real-world evidence, though each program is independently assessed by the FDA.

Collaboration Agreement and Evaluation Timeline

The agreement grants PharmaTher a one-year evaluation period to assess KetaMist for development and commercialization potential. During this time, the parties may negotiate additional agreements, termed "Possible Transactions," subject to mutually acceptable terms, to advance development and commercialization efforts.

This evaluation period enables PharmaTher to conduct thorough due diligence, including reviewing treatment data quality, assessing FDA pathway feasibility, evaluating manufacturing and supply chain considerations, and analyzing commercial viability. The timeframe allows for regulatory engagement and detailed planning before deciding on formal development agreements.

Regulatory Status and Approval Risks

KetaMist is not currently FDA-approved, and its existing clinical use is off-label. While the 9,000-plus patient treatments provide valuable real-world data, these do not constitute FDA-approved clinical evidence. PharmaTher and collaborators must translate this experience into acceptable regulatory formats for approval consideration. The announcement includes cautionary statements highlighting that FDA acceptance of the proposed pathway, suitability of treatment data, and ultimate approval are uncertain.

Risks include the FDA potentially rejecting the proposed strategy, requiring extensive additional studies, and challenges in using retrospective real-world data. The company acknowledges that treatment experience may not meet FDA standards for safety or efficacy, and development may face delays or increased costs, reflecting inherent uncertainties in pharmaceutical regulation.

Positioning Amid Growing Psychedelic Medicine Regulatory Momentum

The collaboration emerges amid heightened U.S. regulatory focus on ketamine and innovative mental health therapies. PharmaTher notes increasing regulatory receptivity to development approaches using real-world data and existing clinical experience to facilitate efficient approval, providing a favorable context for the KetaMist program, albeit with independent FDA evaluation for each submission.

This partnership situates PharmaTher at the convergence of ketamine pharmacology, personalized medicine, and regulatory progress. Pursuing a patient-controlled ketamine platform during a period of evolving regulatory frameworks may offer strategic advantages. PharmaTher's focus on personalized medicines in peptides and psychedelics aligns with industry trends toward targeted therapies, potentially enhancing the commercial and strategic value of the collaboration.

Executive Insights on Strategic Direction

PharmaTher CEO Fabio Chianelli highlighted the collaboration's fit with company strategy, emphasizing KetaMist's combination of physician-developed ketamine treatment, extensive patient use, and a pathway to FDA approval. While initially concentrating on treatment-resistant depression, Chianelli noted the broader franchise potential across multiple ketamine-responsive indications. He expressed confidence that combining real-world data with PharmaTher's prior FDA ketamine experience could accelerate development and unlock value in major markets.

Dr. Curtis W. Cassidy, KetaMist's inventor, remarked that the platform was designed to offer physicians and patients a more personalized, accessible ketamine treatment. With over 9,000 patient treatments, substantial insights into patient response and individualized dosing have been gained. Cassidy affirmed that PharmaTher's shared focus on personalized medicine and regulatory expertise supports advancing KetaMist toward wider access and potential approval, underpinning the collaboration's rationale.